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Galectin-3 (gal3) is a beta-galactoside-binding lectin implicated in cardiac fibrosis and remodeling, elevated in models of failure-prone 
hypertrophied hearts, and with prognostic value in pts with acute & chronic heart failure (HF). The relationship between gal3 and the development of 
HF after ACS is unknown.
Methods:  In a nested case-control study among pts with ACS in PROVE IT-TIMI 22, we identified 100 cases with a hospitalization for new or 
worsening HF. Controls (1:1) were matched for age, sex, ACS type, and randomized treatment. Serum gal3 (BG Medicine, Waltham, MA) was measured 
at baseline (7d post ACS).
Results:  Pts who developed HF had higher baseline gal3, median 16.7 ng/ml (IQR: 14.0-20.6) vs 14.6 (IQR: 12.0-17.6), p = 0.004. Patients 
with baseline gal3 above the median, 15.6 ng/mL, were twice as likely to develop HF, OR 2.1 (95% CI: 1.2-3.6), p = 0.01. Gal3 showed a graded 
relationship with risk of HF (Figure). Cases were more likely to have HTN, DM, and prior HF; after adjustment for these factors, the graded relationship 
with gal3 quartile and HF remained significant, adj-OR 1.4 (95% CI 1.1-1.9; p = 0.02). Each SD increase in gal3 was associated with a 48% increase 
in the adjusted relative odds of HF (p=0.04).
Conclusions:  Galectin-3 was associated with the risk of developing HF following ACS. This finding adds to emerging evidence supporting gal3 as a 
biomarker of adverse remodeling contributing to HF, and supports further investigation of this protein as a novel biomarker and potential therapeutic target. 
